World Health Organization (WHO)

IP Negotiations Monitor 24, April 2018

The IP Negotiations Monitor summarizes the latest developments in multilateral and regional fora where intellectual property negotiations are taking place, and informs on upcoming meetings and events.

(Covering period: January – March 2018)

(more…)

Policy Brief 46, March 2018

Outcomes of the 142nd session of the WHO Executive Board

The 142nd session of the WHO Executive Board discussed several critical public health issues including a recommendation to the WHA to approve the General Program of Work (GPW), the adoption of important decisions relating to access to medicines and research and development and a draft resolution on the preparation of the UN High Level Meeting on Tuberculosis.

(more…)

IP Negotiations Monitor 23, January 2018

The IP Negotiations Monitor summarizes the latest developments in multilateral and regional fora where intellectual property negotiations are taking place, and informs on upcoming meetings and events.

(Covering period: July – December 2017)

(more…)

Research Paper 82, November 2017

The International Debate on Generic Medicines of Biological Origin

The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological products are couched in ever more “technical” and abstruse language that confuses even the World Health Organization (WHO).

(more…)

Policy Brief 45, October 2017

The Value Added of the United Nations General Assembly High–Level Political Declaration on Antimicrobial Resistance

In September 2016, the United Nations General Assembly (UNGA) in New York held a dedicated meeting to muster strong political commitment for an effective global response to the problem of antimicrobial resistance (AMR). As a result, a High-Level Political Declaration on Antimicrobial Resistance was adopted.

(more…)


0

Your Cart